Alamar Biosciences (NASDAQ:ALMR) Now Covered by JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. initiated coverage on shares of Alamar Biosciences (NASDAQ:ALMR) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 25.63% from the company’s previous close.

A number of other equities analysts have also issued reports on ALMR. Wall Street Zen raised Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. TD Cowen assumed coverage on Alamar Biosciences in a report on Tuesday. They issued a “buy” rating for the company. Finally, Stifel Nicolaus started coverage on Alamar Biosciences in a report on Tuesday. They issued a “buy” rating and a $28.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $29.00.

Alamar Biosciences Price Performance

Shares of ALMR stock opened at $23.88 on Tuesday. Alamar Biosciences has a 12-month low of $21.50 and a 12-month high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The company had revenue of $26.04 million during the quarter.

Insiders Place Their Bets

In related news, major shareholder Innovation Fund Gp Illumina II acquired 235,294 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the transaction, the insider owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nicholas Naclerio bought 235,294 shares of Alamar Biosciences stock in a transaction dated Monday, April 20th. The stock was acquired at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the director directly owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. This represents a 86.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.